StockNews.com Begins Coverage on Evoke Pharma (NASDAQ:EVOK)

Equities researchers at StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Stock Performance

Shares of NASDAQ:EVOK opened at $2.20 on Friday. The company has a 50 day moving average price of $3.70 and a two-hundred day moving average price of $4.45. The company has a market capitalization of $3.28 million, a PE ratio of -0.20 and a beta of 0.30. Evoke Pharma has a 52 week low of $2.01 and a 52 week high of $12.32.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.24). The firm had revenue of $3.31 million during the quarter, compared to the consensus estimate of $3.08 million. Evoke Pharma had a negative net margin of 71.32% and a negative return on equity of 308.49%.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently raised its stake in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 148,194 shares of the specialty pharmaceutical company’s stock after buying an additional 91,945 shares during the period. Nantahala Capital Management LLC owned approximately 9.95% of Evoke Pharma worth $655,000 as of its most recent filing with the SEC.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.